Eugenia Leeds
Investor Relations, Recordati
Replay available
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q4 2025 Earnings Call
Recordati Industria Chimica e Farmaceutica S.p.A. (OTC: RCDTF) Q4 2025 earnings conference call, held 2026-02-18. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Rob Cormans
Chief Executive Officer, Recordati
Mike McClellan
Chief Financial Officer, Recordati
Scott Pescatore
Executive Vice President, Rare Diseases, Recordati
Alberto Martinez
Executive Vice President, Specialty and Primary Care, Recordati
Milan Droskowitz
Executive Vice President, R&D, Recordati
Sophia Graf Bull-Nielsen
Analyst, J.P. Morgan
Sian Hammer
Analyst, Jefferies
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Recordati S.p.a..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:03.095 Good afternoon, this is the Chorus Call Conference Operator. 00:00:03.095 -- 00:00:08.523 Welcome and thank you for joining the Recordati Full Year 2025 00:00:08.523 -- 00:00:12.345 Preliminary Results Conference Call. 00:00:12.508 -- 00:00:17.095 As a reminder, all participants are in listen-only mode. 00:00:17.095 -- 00:00:21.759 After the presentation, there will be an opportunity to ask questions. 00:00:22.062 -- 00:00:26.248 Should anyone need assistance during the conference call, they may signal an operator 00:00:26.248 -- 00:00:30.150 by pressing star and zero on their telephone. 00:00:30.372 -- 00:00:35.526 At this time, I would like to turn the conference over to Miss Eugenia Leeds Investor 00:00:35.526 -- 00:00:37.327 Relations of Recordati. 00:00:37.327 -- 00:00:39.470 Please go ahead, Madam. 00:00:39.470 -- 00:00:44.195 Thank you, and good afternoon, everyone. I'm pleased to be here today with Rob Cormans, 00:00:44.195 -- 00:00:49.240 our CEO, and Mike McClellan, our CFO, who will present preliminary results for 00:00:49.240 -- 00:00:51.162 full year 2025. 00:00:51.162 -- 00:00:56.467 Scott Pescatore, Executive Vice President of Rare Diseases, will then provide an update 00:00:56.467 -- 00:01:01.169 on the exciting Isterisa opportunity, as well as the recent deal with Moderna. 00:01:01.169 -- 00:01:06.834 Also joining for the Q&A session will be Alberto Martinez, Executive Vice President 00:01:06.834 -- 00:01:12.760 of Specialty and Primary Care, and Milan Droskowitz, Executive Vice President of R&D. 00:01:12.760 -- 00:01:17.765 As always, the presentation is available in the Investor section of our website. 00:01:17.765 -- 00:01:20.388 It is now my pleasure to pass the call over to Rob. 00:01:20.388 -- 00:01:22.249 Pl...